3 Beaten-Up Biotech Stocks: Are They Bargains?


The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. Is the pessimism justified, or has the market underestimated the potential value drivers within these companies' drug development pipelines? Let's take a cool-headed look at each to see if there's something for long-term value investors to get excited about. This biotech took a few steps back earlier this summer, when one of its clinical-stage candidates, varlilumab, generated less than thrilling results for 21 patients with advanced-stage colorectal and ovarian cancer when given in combination with Opdivo from Bristol-Myers Squibb .



from Biotech News